Abstract: A compressed air delivery system includes a source of pressurized air and a piping system adapted to deliver pressurized air from the source of pressurized air to a compressed air outlet in or accessible from a workstation. A pneumatic object in or accessible from the workstation utilizes compressed air and is connectable to the compressed air outlet. A leak reduction system includes a workstation use detector, a controller, and a compressed air outlet valve moveable between an open position where compressed air flows through the compressed air outlet and a closed position where compressed air does not flow through the compressed air outlet. The workstation use detector provides a workstation use signal related to whether or not the workstation is in use to the controller, and wherein the controller controls operation of the compressed air outlet valve in response to the signal.

Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

Abstract: In some embodiments, the invention includes therapeutic combinations of antiviral active pharmaceutical ingredients and anti-inflammatory active pharmaceutical ingredients, including steroids, and methods of using of the therapeutic compositions in the treatment of viral infections.

Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

Abstract: The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a):Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologic ally active agents.

Abstract: Disclosed herein are PVP-I-containing compositions, as well as methods of making such compositions, which provide reliable stability for PVP-I preparations, including preparations comprising PVP-I and one or more additional components.

Abstract: Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions.

Abstract: Systems, methods, and computer-program products identify clinical data corresponding to a plurality of patients located within a common health care delivery unit, and apply one or more rules to at least some of the clinical data using at least one quality and/or safety measure-specific specification. Based on the application of the rules, one or more care indicators corresponding to the plurality of patients are displayed in a single interface, the one or more care indicators indicating whether one or more of the patients is receiving appropriate care.

Abstract: The invention includes a preserved ophthalmic preparation comprising povidone-iodine (PVP-I) at a concentration sufficient to preserve the ophthalmic preparation, and at least one member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial compound, an anti-allergy compound, and an anti-glaucoma compound. The invention also includes adding PVP-I to an ophthalmic composition in order to preserve the composition, wherein the PVP-I is added at a concentration sufficient to preserve the composition.

Abstract: Disclosed are compositions and methods comprising povidone-iodine and a cooling-effective amount of a chemical agent. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye.

Abstract: Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans.

Abstract: The invention includes a preserved ophthalmic preparation comprising povidone-iodine (PVP-I) at a concentration sufficient to preserve the ophthalmic preparation, and at least one member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial compound, an anti-allergy compound, and an anti-glaucoma compound. The invention also includes adding PVP-I to an ophthalmic composition in order to preserve the composition, wherein the PVP-I is added at a concentration sufficient to preserve the composition.

Abstract: Systems, methods, and computer-program products identify clinical data corresponding to a plurality of patients located within a common health care delivery unit, and apply one or more rules to at least some of the clinical data using at least one quality and/or safety measure-specific specification. Based on the application of the rules, one or more care indicators corresponding to the plurality of patients are displayed in a single interface, the one or more care indicators indicating whether one or more of the patients is receiving appropriate care.

Abstract: Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans.

Abstract: This invention relates to the identification of a nucleic acid molecule. In particular, this invention relates to a method of using an oligonucleotide designed to a variable region of a nucleic acid molecule to identify A nucleic acid molecule.

Abstract: Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans.

Abstract: The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N?-acyl derivatives of N?(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic N?-acyl derivatives of N?-acyl derivatives of N?(4-amino-4-deoxypteroyl)-L-ornithine compounds.